Atlas Trials

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

Clinical trial NCT05345327 · RECRUITING

Trial details

NCT number
NCT05345327
Sponsor
The George Institute
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Type 2 Diabetes
Start date
2023-01-01
Primary completion
2026-06-30
Enrollment
994

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.